Notable Labs Ltd
NASDAQ:NTBL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
P
|
PCTEL Inc
F:PEW
|
US |
|
Trelleborg AB
STO:TREL B
|
SE |
|
S
|
Senheng New Retail Bhd
KLSE:SENHENG
|
MY |
|
S
|
SBI Cards and Payment Services Ltd
NSE:SBICARD
|
IN |
Notable Labs Ltd
Total Liabilities & Equity
Notable Labs Ltd
Total Liabilities & Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Notable Labs Ltd
NASDAQ:NTBL
|
Total Liabilities & Equity
$11m
|
CAGR 3-Years
-45%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
N/A
|
|
|
Kamada Ltd
NASDAQ:KMDA
|
Total Liabilities & Equity
$378.7m
|
CAGR 3-Years
6%
|
CAGR 5-Years
12%
|
CAGR 10-Years
14%
|
|
|
Enlivex Therapeutics Ltd
NASDAQ:ENLV
|
Total Liabilities & Equity
$20.9m
|
CAGR 3-Years
-34%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-1%
|
|
|
Urogen Pharma Ltd
NASDAQ:URGN
|
Total Liabilities & Equity
$200.5m
|
CAGR 3-Years
14%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
Entera Bio Ltd
NASDAQ:ENTX
|
Total Liabilities & Equity
$17.4m
|
CAGR 3-Years
4%
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
|
|
Pluri Inc
NASDAQ:PLUR
|
Total Liabilities & Equity
$30.6m
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-6%
|
|
Notable Labs Ltd
Glance View
Notable Labs Ltd is a IL-based company operating in Biotechnology industry. Notable Labs Ltd, formerly Vascular Biogenics Ltd, is an Israel-based clinical-stage biopharmaceutical company committed to developing next-generation, targeted medicines for difficult-to-treat medical conditions. The firm has created a pipeline of therapeutics that address cancer and immune-inflammatory diseases with the goal of significantly improving patient outcomes and overcoming the limitations of approved treatments. The firm's product candidates are built off of two platform technologies: Vascular Targeting System (VTS), a gene-based technology targeting newly formed blood vessels, and Monocyte Targeting Technology (MTT), an antibody-based technology able to specifically inhibit monocyte migration for immune-inflammatory applications.
See Also
What is Notable Labs Ltd's Total Liabilities & Equity?
Total Liabilities & Equity
11m
USD
Based on the financial report for Jun 30, 2024, Notable Labs Ltd's Total Liabilities & Equity amounts to 11m USD.
What is Notable Labs Ltd's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 5Y
-28%
Over the last year, the Total Liabilities & Equity growth was -55%. The average annual Total Liabilities & Equity growth rates for Notable Labs Ltd have been -45% over the past three years , -28% over the past five years .
